[Down's syndrome and leukemia].
OBJECTIVE
Children with Down's Syndrome (DS) have a high risk for leukemia and need special clinical management. For this reason we have reviewed our experience.


METHODS
All children with DS diagnosed a having acute leukemia during a 21-year period were reviewed retrospectively. Treatment was administered according to current protocols in our unit at the time of diagnosis without any initial modification.


RESULTS
There were 13 children with DS and acute leukemia [6 ALL, 4 AML and 3 transient leukemias (TL)]. No patient presented CNS leukemia at diagnosis. All children with AML and DS were under three years of age and standard treatments did not achieve satisfactory results. TL regressed in two newborns without developing AMKL later. Five out of six patients with DS and ALL achieved complete remission. Currently, 4 of these children are alive and off therapy. Toxicities related to treatment were observed in almost all of the patients.


CONCLUSIONS
Children with DS suffer a higher risk of developing leukemia. They should receive standard protocols, but aggressive supportive care might be provided as they have a higher incidence of treatment related toxicities. Prognosis of these children is similar or even better in some cases than children without DS. TL is a true neoplastic process capable of spontaneous remission and it can progress to AMKL.
Bermúdez Cortés
M
M
Servicio de Oncología Pediátrica, Hospital Infantil Universitario La Fe, Valencia.
Verdeguer Miralles
A
A
Jovaní Casano
C
C
Cañete Nieto
A
A
Fernández
J M
JM
Ferris Tortajada
J
J
Castel Sánchez
V
V
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000150:complications*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007938:Leukemia / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D012189:Retrospective Studies
D000970:Antineoplastic Agents
Síndrome de Down y leucemia.